Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of aescin in treatment of non-alcoholic fatty liver diseases

A kind of escin, non-alcoholic technology, applied in the application field of escin in the treatment of non-alcoholic fatty liver disease

Inactive Publication Date: 2021-04-16
JILIN UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As a natural plant drug, aescin has significant anti-inflammatory and lipid peroxidation inhibitory effects, but its effects on reducing liver damage, relieving abnormal liver lipid metabolism, and relieving hepatic oxidative stress have not been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of aescin in treatment of non-alcoholic fatty liver diseases
  • Application of aescin in treatment of non-alcoholic fatty liver diseases
  • Application of aescin in treatment of non-alcoholic fatty liver diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023]Example 1: HepG2 cell culture

[0024]1 Medium-producing formulation: 10% FBS, 1% teeth, 4.5 g / L of DMEM medium of glucose;

[0025]2 inoculation: Turn HepG2 cells in 6-well plate, each hole density of 1 × 106Cells and placed them in a 37 ° C cell incubator containing 5% carbon dioxide and 95% air;

[0026]3 Hunger cells: After 12 h, the medium was removed, replaced with only 4.5 g / l glucose DMEM medium, hungry HepG2 cells for 3h;

[0027]4 Experimental group: HepG2 cells were incubated with 2 μm seven-leaf vessel (1000 μm free fatty acid (oleic acid: palmitic acid = 2: 1) co-incubated cell 24 h; divided into a blank group (DMEM medium), the model group (1000 μm free fatty acid ), The control group (2 μm seven-leaf saponin), the experimental group (2 μm seven-blasside + 1000 μm free fatty acid).

Embodiment 2

[0028]Example 2: AML12 cell culture

[0029]1 Medium production: 1ml, ITS LiquidMedia Ssupplement (Sigma, 13146) 1ml, 40 ng / l DEXAMETHASONE (Sigma, D4902-100MG), FBS (Gibeo) 10ML ;

[0030]2 Inoculated: AML12 cells were inoculated into the six-hole plate and placed in a cell incubator containing 5% carbon dioxide and 95% air;

[0031]3 Hunger cells: After 12 h, the medium was removed, replaced with DMEM / F12 medium, hungry AML12 cells for 3h;

[0032]4 Experimental group: incubation AML12 cells were incubated with 2 μm seven-leaf saponins and then 1000 μm free fatty acid (oleic acid: palmitic acid = 2: 1) co-incubated cell 24 h; divided into a blank group (DMEM / F12 medium), the model group (1000 μm) Free fatty acids), control group (2 μm seven-leaf saponin), experimental group (2 μm seven-blasside + 1000 μm free fatty acid).

Embodiment 3

[0033]Example 3: Determination of TG content in HepG2 cells

[0034]1 Collect cells, 1000 rpm / min centrifuge 10min, discard the supernatant, and sedate the cells;

[0035]2 Clean 1 ~ 2 times, 1000 rpm / min for 10 min, abandoned the supernatant;

[0036]3 cells are broken, add 0.2 ml of the like-phosphate buffer for homogenate, ice water bath (power 300W, 3 ~ 5S / time, interval 30s, repeating 3 ~ 5 times);

[0037]4 Preparation of homogenies without centrifugation directly according to the kit manufacturer's manual. The determination absorbance was performed using the enzyme standard.

[0038]5 The TG content measured is attached.figure 1 . Attachfigure 1 The results showed that the free fatty acid of 1000 μm can significantly increase the Tg level in HepG2 cells as compared with the blank group. Compared with the model group, the seven-leaf saponin drug experiment can significantly reduce the Tg level in HepG2 cells (P<0.05).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of aescin in treatment of non-alcoholic fatty liver diseases. Pharmacological experiments in the invention show for the first time that aescin has a good treatment effect on a tyloxapol-induced non-alcoholic fatty liver disease mouse model and an oleic acid-induced and palmitic acid-induced hepatocyte lipid accumulation model. Experimental results prove that aescin can inhibit the accumulation of lipid in HepG2 and AML12 cells, and can reduce the content of TG in the liver of an NAFLD mouse, reduce ALT and AST in serum and increase SOD. Therefore, the aescin is exact in curative effect, remarkable in effect and low in side effect when used for treating the NAFLD, and has wide medical application prospects.

Description

Technical field[0001]The present invention relates to the field of biomedicine, and more particularly to the application of seven-blassosins in the treatment of non-alcoholic fatty liver disease.Background technique[0002]Non-alcoholic fatty liver disease (NAFLD) is due to excessive accumulation of lipids, which causes fat degeneration in the liver, and a small amount of or without drinking, and there is no obvious clinical symptom. NAFLD is mainly composed of simple fatty liver and its evolved non-alcoholic fatty hepatitis (NASH) and fatty cirrhosis. Simple fatty liver is mainly due to liver lipid accumulation caused by hepatocyte inflammation and lipid peroxidation on the basis of hepatocytes, resulting in non-alcoholic fatty hepatitis, with necrotic necrosis of hepatocytes and The increase in the ancestral cell can result in a complete collapse of liver leaf structure and function, and the fake leaflet will substitution and form fibrosis, and finally form a similar nodule cirrhosi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P1/16
Inventor 冯海华韦云飞严斯如金美玉张迪覃海燕王齐赵立磊程佳奇
Owner JILIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com